Core Insights - The company reported net sales of €1.62 billion, driven by growth in Composite Materials, Technology Solutions, and Novecare, with a resilient underlying EBITDA of €311 million, reflecting a 5% sequential increase [1][3][5] Financial Performance - Net sales for Q1 2025 were €1,619 million, showing a slight decrease of 0.3% year-on-year and an increase of 1.3% sequentially [2][5] - Gross profit was €514 million, down 11.9% year-on-year, with a gross profit margin of 31.7%, which is a decrease of 420 basis points year-on-year but an increase of 160 basis points sequentially [2][5] - Underlying EBITDA decreased by 14.2% year-on-year to €311 million, with an underlying EBITDA margin of 19.2%, down 310 basis points year-on-year but up 60 basis points sequentially [2][5] - Operating cash flow was €176 million, while free cash flow was €37 million, impacted by capital expenditures [2][5] Market Outlook - The company maintains its outlook for FY 2025, expecting continued macroeconomic and demand uncertainty due to ongoing tariff and global trade tensions [4][6] - The second quarter of 2025 is anticipated to have challenging visibility, with demand uncertainty expected to persist across most end markets [9][10] - The company plans to accelerate restructuring and cost-saving initiatives, including a proposed reduction of approximately 200 positions, aiming for over €200 million in run rate savings by the end of 2026 [8][10] Strategic Initiatives - The company is implementing mitigation measures to manage direct exposures to tariff impacts, including tariff surcharges and refining supply chain exposures [7] - The focus remains on executing controllable initiatives, such as completing separation processes and making disciplined, high-return investments [4][6]

Core Insights - The company reported strong first quarter results, with a year-to-date Directional revenue of US$1,103 million, reflecting a 27% increase compared to the same period last year [8][9]. - The Directional backlog stands at US$35.1 billion, supported by firm contracts and inflation protection, with an expected cash generation of US$9.5 billion [3][4]. - A cash dividend of EUR150 million was paid, and a share buyback program of EUR141 million is underway, with a minimum of US$1.7 billion cash return to shareholders expected by 2030 [3][19][20]. Financial Overview - Directional revenue increased to US$1,103 million, up 27% from US$871 million in 1Q 2024, driven primarily by the Turnkey segment [9][10]. - Directional Turnkey revenue reached US$627 million, a 98% increase from US$316 million in the same period last year [10]. - Directional Lease and Operate revenue was US$476 million, down from US$554 million, attributed to the sale of FPSOs Prosperity and Liza Destiny [11]. Project and Operational Update - The company is on track to deliver three major vessels in 2025, with FPSO Almirante Tamandaré achieving first oil in February 2025, and FPSOs Alexandre de Gusmão and ONE GUYANA expected to follow [4][12]. - The Fast4Ward program has successfully ordered ten MPF hulls, with four currently in operation and another four delivered for ongoing projects [15]. - Fleet uptime for the year-to-date was reported at 99.5%, consistent with historical performance [15]. Strategic Initiatives - A strategic collaboration agreement with Microsoft was signed to develop carbon-free floating power solutions, focusing on deploying floating gas-to-power solutions with integrated carbon capture and storage [6][17]. - The company aims to introduce a near zero emission FPSO by the end of 2025, having received "Approval in Principle" from the American Bureau of Shipping for its design [18]. Guidance - The company maintains its 2025 Directional revenue guidance at above US$4.9 billion, with expectations of over US$2.2 billion from the Lease and Operate segment and around US$2.7 billion from the Turnkey segment [21]. - Directional EBITDA guidance for 2025 is also maintained at approximately US$1.55 billion [21].

KUALA LUMPUR, MALAYSIA, May 15, 2025 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines, today announced its first quarter financial results and provided a business update. “As part of the Company’s efforts to reduce operating costs it has determined to focus on the development of the plogosertib (“plogo”) clinical program only. Accordingly, on March 10, 2025, the Company repurchased certa ...

Lerøy Seafood Group ASA reports a consolidated operational EBIT of MNOK 1 049 for the first quarter of 2025, up from MNOK 842 in the same period last year. OPERATIONAL IMPROVEMENTS NOW VISIBLE IN FARMINGThe Farming segment delivered an operational EBIT of MNOK 789 in the quarter. “This is a strong performance in a quarter marked by significantly lower spot prices for salmon and trout compared to the same period last year. Improvements in genetics, roe and smolt quality, use of shielding technology, and gene ...

Group 1 - The 2025 Brand Global Communication Conference was held in Shanghai, focusing on enhancing the global influence of Chinese brands in overseas markets [1][2] - A report on the global brand communication capability of Chinese brands was released, providing pathways for promoting high-quality brand globalization [2][5] - Significant progress in brand development and international communication has been observed in urban culture, finance, and the gaming and toy sectors since 2024 [3][5] Group 2 - The report includes the first in-depth regional analysis, unveiling the 2025 Shanghai cultural brand global communication capability ranking, highlighting top brands in cultural tourism, design, film and television, technology, and urban intellectual property [4] - The conference marks the third consecutive year of releasing the research report, focusing on the overall ranking and changes in Chinese brands' global communication capability over the past three years [5] - Strong performances in the automotive, artificial intelligence, and consumer electronics sectors were noted in the data compiled from the 2023 and 2024 rankings [5]

Core Insights - VEON reported a total revenue growth of 8.9% year-on-year to USD 1,026 million for Q1 2025, with underlying local currency growth at 12.9% [2][9] - EBITDA increased by 13.7% year-on-year to USD 439 million, with a 10.4% increase in underlying local currency terms [4][9] - Direct digital revenue grew significantly by 50.2% year-on-year to USD 147 million, representing 14.3% of total revenues for the quarter [4][9] Financial Performance - The company achieved a year-on-year revenue growth of 8.9% in reported currency and 12.9% in local currency, adjusted for the impact of a cyberattack in Ukraine and the deconsolidation of TNS+ in Kazakhstan [2][3] - EBITDA for the quarter was USD 439 million, reflecting a 13.7% increase in reported currency and a 10.4% increase in underlying local currency terms [4][9] - Total cash and cash equivalents as of March 31, 2025, amounted to USD 1,775 million, with net debt to LTM EBITDA declining to 1.23x [5][9] Capital Expenditure and Outlook - Capex increased by 8.3% year-on-year, with a capex intensity of 13.1% [5] - The company maintains its FY25 outlook, expecting underlying local currency revenue growth of 12% to 14% and EBITDA growth of 13% to 15% [6] Share Buyback Program - VEON commenced the second phase of its share buyback program in March 2025, amounting to up to USD 35 million, following the completion of the first phase [7] Strategic Focus - The company emphasizes disciplined execution and innovation, aiming to enhance customer experiences through technology-driven services [10][11]

Dividend Payment Information - AS Harju Elekter Group will close the list of shareholders for dividend payment on 21 May 2025 at the end of the working day of the Nasdaq CSD Estonian settlement system [1] - The ex-date, or the day of change of the rights related to the shares, is set for 20 May 2025, meaning new owners of the shares from that date will not be entitled to dividends for the year 2024 [1] - The company will pay a dividend of 0.15 euros per share on 28 May 2025 [1]

Company Overview - Primega Group Holdings Limited is changing its ticker symbol from "PGHL" to "ZDAI" on the Nasdaq Stock Market, effective May 16, 2025, reflecting its evolving identity and strategic vision [1][3] - The company is based in the Cayman Islands and operates through its Hong Kong subsidiary, Primega Construction Engineering Co. Limited, focusing on environmentally friendly transportation services and minimizing construction waste [5] Strategic Focus - Primega Group Holdings Limited is venturing into technological advancements, including hotel marketing software development, digitized supply chain platforms, AI and IoT integration, cloud computing, and intelligent engineering equipment [2] - The new ticker symbol "ZDAI" symbolizes the company's commitment to innovation, growth, and excellence [1][3] Leadership Statement - Tan Yu, Chairman of Primega Group Holdings Limited, expressed excitement about the new ticker symbol, indicating it aligns with the company's corporate objectives and future trajectory, marking an important milestone for growth and success [3]

Core Insights - Mesoblast has received seven years of orphan-drug exclusive approval from the FDA for Ryoncil (remestemcel-L) to treat steroid-refractory acute graft versus host disease (SR-aGvHD) in pediatric patients aged 2 months and older [1][5] - The FDA's approval grants Mesoblast statutory exclusivity, preventing the approval of other mesenchymal stromal or stem cell products for this indication during the exclusivity period [2] - Mesoblast holds biologic exclusivity that prevents other sponsors from referencing the Ryoncil biologic license application until December 2036, providing a barrier against biosimilar market entry [2] - The company has a strong U.S. intellectual property position on MSC composition, manufacturing, and indications, providing commercial protection against competitors through 2044 [3][7] Company Overview - Mesoblast is a leader in developing allogeneic cellular medicines for severe inflammatory conditions, utilizing proprietary mesenchymal lineage cell therapy technology [4] - Ryoncil is the first FDA-approved MSC therapy for SR-aGvHD in pediatric patients [5] - The company is also developing additional cell therapies for other inflammatory diseases and has established commercial partnerships in Japan, Europe, and China [6] Intellectual Property and Manufacturing - Mesoblast has over 1,000 granted patents or patent applications covering various aspects of MSC technology, expected to provide commercial protection through at least 2044 [7] - The company's proprietary manufacturing processes yield industrial-scale, cryopreserved, off-the-shelf cellular medicines, ensuring availability to patients worldwide [8]

Core Viewpoint - Cavco Industries, Inc. is set to release its earnings for the fourth quarter and fiscal year ending March 29, 2025, on May 22, 2025, with a subsequent live discussion scheduled for May 23, 2025 [1]. Company Overview - Cavco Industries, Inc. is headquartered in Phoenix, Arizona, and specializes in designing and producing factory-built housing products, primarily distributed through a network of independent and company-owned retailers [3]. - The company is recognized as one of the largest producers of manufactured and modular homes in the United States, based on reported wholesale shipments [3]. - Cavco also leads in the production of park model RVs, vacation cabins, and factory-built commercial structures [3]. - The finance subsidiary, CountryPlace Mortgage, is an approved seller/servicer for Fannie Mae and Freddie Mac, and a Ginnie Mae mortgage-backed securities issuer, offering various mortgage products [3]. - The insurance subsidiary, Standard Casualty, provides property and casualty insurance to owners of manufactured homes [3].